STEVE BAGSHAW, NON-EXECUTIVE CHAIRMAN OF FUJIFILM DIOSYNTH BIOTECHNOLOGIES RECOGNIZED IN NEW YEAR’S HONORS LIST 2021
Billingham, United Kingdom, January 4, 2021 – FUJIFILM Diosynth Biotechnologies, is pleased to share that Steve Bagshaw, non-executive chairman of FUJIFILM Diosynth Biotechnologies, has been awarded Commander of the Most Excellent Order of the British Empire (CBE) for Services to the U.K. Manufacturing and Biotechnology Sector in the New Year’s Honors List 2021.
The New Year Honors List 2021, published on December 31, 2020, recognizes individuals within the public sector and community for their extraordinary contributions in all four nations of the United Kingdom throughout 2020 and beyond.
“I am very honored to receive the CBE award in the New Years Honors List 2021, alongside countless individuals that are dedicated to building a healthier tomorrow,” said Steve Bagshaw, non-executive chairman, FUJIFILM Diosynth Biotechnologies. “This recognition comes at a time when our U.K. and global biotechnology and manufacturing teams are working not only to develop and make the vaccines we all need, but also the medicines, food, biochemicals, fuels and materials that will help us create a sustainable and healthy future for our planet.”
Steve Bagshaw has been with FUJIFILM Diosynth Biotechnologies for sixteen years, he previously held the position of chief executive officer, prior to his retirement and position as non-executive chairman. During his tenure, Bagshaw helped establish FUJIFILM Diosynth Biotechnologies as a world leading Contract Development and Manufacturing Organization (CDMO) providing end-to-end services for the development and manufacture of biologics, viral vaccines and viral vectors that currently employs ~3000 staff globally, with 850 located in Billingham in the North East of England.
In addition to his role at FUJIFILM Diosynth Biotechnologies, Bagshaw has spent the last seven years as chair of U.K.’s Industrial Biotechnology Forum bringing together the U.K. government, industry, academia, and funding agencies to ensure that the region remains a significant global player in industrial biotechnology and life sciences sectors. Additionally, Steve has spent the last four years working across all the sectors of the bio-economy to enable the launch of the U.K. Bio-Economy strategy in 2018 and now as co-chair of the U.K. Bio-economy Governance Council overseeing its implementation.
“All of us at FUJIFILM Diosynth Biotechnologies are thrilled that Steve Bagshaw is recognized for his tireless efforts to foster collaboration within the bio-economy to advance life sciences research and therapeutics that will have a profound impact on patients,” shared Martin Meeson, chief executive officer, FUJIFILM Diosynth Biotechnologies. “We are deeply honored that one of our own has received this honor, and we send our warmest congratulations to Steve.”
Most recently, Steve has been working on the U.K.’s Vaccines Task Force to ensure the deployment of population scale doses of COVID-19 vaccines for both the U.K. and the world.
Steve serves as a non-executive board member of Centre for Process Innovation (CPI), and Arcinova, and was recently appointed to the Council of the U.K.’s Biotechnology and Biological Sciences Research Council (BBSRC) part of U.K. Research and Innovation – the U.K. Government oversight body for funding and activities.
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Corporation is an operating company of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $21 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com